Asia
MoonLake revives FDA push; biotech trio to debut in Hong Kong
MoonLake Immunotherapeutics; Sonelokimab; Hidradenitis Suppurativa; FDA Type B meeting; Biologics License Application; BLA H2 2026; VELA-1 trial; VELA-2 trial; MIRA trial; HS drug approval pathway; investor day February 23 2026; Hong Kong biotech IPOs; Hong Kong listing; Asia biotech capital markets
Kyowa Kirin Divests China Unit and Reduces Small-Molecule Discovery Efforts
Kyowa Kirin, China business, small-molecule discovery, restructuring, Asia Pacific, pharmaceuticals